Sign In
Buy OFIX
$9.72
+0.0100 (+0.103%)
At Close: Jun 03, 2026
Orthofix to Participate at Canaccord Genuity 45th Annual Growth Conference
07:00am, Wednesday, 16'th Jul 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate at the Canaccord Genuity 45th An
Orthofix to Report Second Quarter 2025 Financial Results
07:00am, Tuesday, 15'th Jul 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its second quarter 2025 financial results on
Orthofix Announces Global Commercial Launch of the TrueLok Elevate Transverse Bone Transport System
07:00am, Tuesday, 17'th Jun 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the global commercial launch of the TrueLok™ Elevate Transverse
Orthofix Medical Inc. (OFIX) Q1 2025 Earnings Call Transcript
02:39pm, Tuesday, 06'th May 2025
Orthofix Medical Inc. (NASDAQ:OFIX ) Q1 2025 Earnings Conference Call May 6, 2025 8:30 AM ET Company Participants Julie Dewey - Chief Investor Relations and Communications Officer Massimo Calafiore -
Orthofix (OFIX) Reports Q1 Loss, Tops Revenue Estimates
09:35am, Tuesday, 06'th May 2025
Orthofix (OFIX) came out with a quarterly loss of $0.08 per share versus the Zacks Consensus Estimate of a loss of $0.17. This compares to loss of $0.46 per share a year ago.
Orthofix Reports First Quarter 2025 Financial Results
07:00am, Tuesday, 06'th May 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the first quarter ended March 31, 2025, u
Orthofix Receives 510(k) Clearance and CE Mark for TrueLok Elevate Transverse Bone Transport System
08:00am, Wednesday, 19'th Mar 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) cle
Kuehn Law Encourages Investors of Orthofix Medical Inc. to Contact Law Firm
11:27am, Tuesday, 18'th Mar 2025
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Kuehn Law, PLLC, a shareholder litigation law firm, is investigating whether certain officers and directors of Orthofix Medical Inc. (NASDAQ: OFIX) breache
Orthofix Announces Appointment of Vickie Capps to Board of Directors
08:00am, Wednesday, 12'th Mar 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced the appointment of Vickie Capps to the Company's Board of Director
Orthofix to Participate in the 37th Annual Roth Conference
07:00am, Monday, 03'rd Mar 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the 37th Annual Roth Conferen
Orthofix (OFIX) Q4 Earnings Lag Estimates
09:35am, Tuesday, 25'th Feb 2025
Orthofix (OFIX) came out with quarterly earnings of $0.02 per share, missing the Zacks Consensus Estimate of $0.06 per share. This compares to loss of $0.10 per share a year ago.
Orthofix Reports Fourth Quarter and Full-Year 2024 Results and Provides 2025 Financial Guidance
07:00am, Tuesday, 25'th Feb 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today reported its financial results for the fourth quarter and full-year ended De
Orthofix to Participate in the Canaccord Genuity 2025 Musculoskeletal Conference
07:05am, Monday, 17'th Feb 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that the Company will participate in the Canaccord Genuity 2025 Mu
Orthofix to Report Fourth Quarter and Full-Year 2024 Financial Results
07:00am, Tuesday, 28'th Jan 2025
LEWISVILLE, Texas--(BUSINESS WIRE)--Orthofix Medical Inc. (NASDAQ:OFIX), a leading global medical technology company, today announced that it will release its fourth quarter and full-year 2024 financi
Bronstein, Gewirtz & Grossman, LLC Encourages Orthofix Medical Inc. (OFIX) Investors to Inquire about Securities Investigation
03:45pm, Wednesday, 04'th Dec 2024
NEW YORK, NY / ACCESSWIRE / December 4, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Orthofix Medical Inc. ("Orthofix" or "the Company") (NASD
